What is Amici Pharmaceuticals?
Based in Melville, N.Y., Amici Pharmaceuticals specializes in the acquisition and development of niche pharmaceutical products. Leveraging a robust network of development and manufacturing partners, the company focuses on delivering high-quality ophthalmic and oral solid dosage forms. Amici Pharmaceuticals is committed to exceptional customer service, ensuring all its finished products originate from facilities adhering to generally accepted good manufacturing practices. A recent product launch includes metolazone tablets, a generic equivalent to Zaroxolyn, which treats salt and water retention associated with conditions like congestive heart failure and renal diseases, available in 2.5-, 5-, and 10-mg strengths.
How much funding has Amici Pharmaceuticals raised?
Amici Pharmaceuticals has raised a total of $83K across 1 funding round:
Debt
$83K
Debt (2021): $83K with participation from PPP
Key Investors in Amici Pharmaceuticals
PPP
Public-Private Partnership
What's next for Amici Pharmaceuticals?
With significant capital infusion at a crucial growth phase, Amici Pharmaceuticals is strategically positioned to accelerate its product pipeline and expand its market reach. The company's focus on acquiring and developing niche generic products, coupled with its commitment to quality and customer service, suggests a trajectory aimed at capturing specific market segments. Future endeavors will likely involve further product acquisitions, potential strategic partnerships for enhanced distribution, and continued investment in manufacturing capabilities to meet growing demand for its specialized offerings.
See full Amici Pharmaceuticals company page
